{"id":"W2589184568","doi":"10.1111/hae.13191","title":"Pharmacokinetics of a novel extended half‐life glyco<scp>PEG</scp>ylated factor <scp>IX</scp>, nonacog beta pegol (N9‐<scp>GP</scp>) in previously treated patients with haemophilia B: results from two phase 3 clinical trials","year":2017,"lang":"en","type":"article","venue":"Haemophilia","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novo Nordisk; Baxalta; CSL Behring; LEO Pharma Research Foundation; Biogen Idec; Roche; Bayer; Chugai Pharmaceutical; Pfizer; Alnylam Pharmaceuticals; Boehringer Ingelheim","keywords":"Medicine; Haemophilia; Haemophilia B; Pharmacokinetics; Factor IX; Dosing; Population; Haemophilia A; Half-life; Gastroenterology; Internal medicine; Pediatrics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.003741859,0.001910496,0.005328035,0.001103601,0.0006534806,0.0003434326,0.001903995,0.001340713,0.0001011882],"category_scores_gemma":[0.0374957,0.001443108,0.001326771,0.001144547,0.001570391,0.0007352871,0.0007236875,0.002356593,0.0002804023],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004157429,"about_ca_system_score_gemma":0.001376565,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001671228,"about_ca_topic_score_gemma":0.0003564353,"domain_scores_codex":[0.9841729,0.001616204,0.005550567,0.002982105,0.003056946,0.002621326],"domain_scores_gemma":[0.9789639,0.009369015,0.003490326,0.003903351,0.00172509,0.00254836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01502914,0.05234314,0.7266982,0.001349954,0.01117891,0.00657986,0.008723836,0.000130191,0.05733424,0.00008235723,0.04343043,0.07711975],"study_design_scores_gemma":[0.3448753,0.01097316,0.5289288,0.003063184,0.004628728,0.00009655109,0.000748141,0.006016762,0.07981949,0.0002403613,0.01993767,0.0006718571],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799179,0.001133989,0.00005165749,0.0008788944,0.001037347,0.008003476,0.004897881,0.0003394223,0.003739404],"genre_scores_gemma":[0.9839537,0.001388483,0.001238885,0.0002642199,0.001542203,0.00024152,0.003697922,0.0003769211,0.007296131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3298461,"threshold_uncertainty_score":0.9999558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1451380483141109,"score_gpt":0.431994202506221,"score_spread":0.2868561541921101,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}